NCT06926205
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06926205
Title CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL (GELLC9RICHTER)
Acronym GELLC9RICHTER
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GELLC (Grupo Español de Leucemia Linfocítica Crónica)
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.